Every 10-Q that Viking Therapeutics, Inc (VKTX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow VKTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VKTX filings page.
Viking Therapeutics, a clinical-stage biotech focused on metabolic and endocrine disorders, reported no revenue and a sharply higher net loss as development spending accelerated. For the six months ended June 30, 2026, net loss was $286.3 million versus $111.2 million a year earlier, driven by a rise in research and development expense to $265.9 million from $101.5 million and general and administrative costs of $30.8 million. For the three-month period, net loss was $128.0 million, or $1.10 per share.
Liquidity remains substantial, with $125.8 million in cash and cash equivalents and $375.9 million in short-term investments at June 30, 2026, despite $239.1 million of operating cash outflow in the first half. The company raised $34.2 million via at-the-market stock sales and had 116.7 million common shares outstanding as of July 15, 2026. Development advanced for obesity candidate VK2735 (Phase 3 injectable and Phase 2 oral data), NASH drug VK2809 (positive 52-week histology), amylin agonist VK3019 (Phase 1 initiated), and X‑ALD candidate VK0214, while a new $500 million share repurchase program over three years was authorized after period-end.
Viking Therapeutics reported a much larger quarterly loss as it ramped up late‑stage obesity trials and faced a new licensing dispute. For the three months ended March 31, 2026, the company recorded a net loss of $158.3 million, compared with $45.6 million a year earlier, driven mainly by higher research and development spending.
R&D expenses rose to $150.2 million as Viking advanced its Phase 3 VANQUISH-1 and VANQUISH-2 studies of obesity drug VK2735 and continued work on other metabolic programs. The company ended the quarter with $118.1 million in cash and $484.8 million in short‑term investments, supporting an equity base of $501.9 million. Viking also highlighted a dispute with Ligand Pharmaceuticals, which has notified Viking that it is purporting to terminate the license for the TR‑Beta program, including VK2809; Viking states it believes Ligand has no such right and plans to vigorously defend its position.
Viking Therapeutics (VKTX) filed its Q3 2025 report, showing higher R&D as programs advanced and a wider loss. For the quarter, net loss was $90.8 million, or $0.81 per share, driven by research and development expense of $89.9 million and general and administrative expense of $8.6 million. There was no revenue.
Liquidity remained strong with cash and cash equivalents of $100.4 million and short‑term investments of $614.2 million as of September 30, 2025. For the nine months, the company used $193.4 million in operating cash. Stockholders’ equity was $713.0 million.
Capital markets tools are in place: an S‑3 shelf effective July 2023, ATM capacity remaining up to $151.9 million, and a $250.0 million repurchase program authorized in February 2025 (no repurchases in Q3). The March 2024 offering provided $597.1 million net proceeds. Shares outstanding were 113,036,344 as of October 15, 2025.
Operationally, Viking entered multi‑year manufacturing agreements for VK2735 with prepayments from 2025 to 2028 credited against future orders. A subsequent lease amendment expands headquarters space, with $63,000 monthly base rent starting on the later of substantial completion or April 1, 2026.